Method for synthesizing 3-hydroxy trilobatin through double-enzyme cascade catalysis
The enzyme-catalyzed reaction of naringin dihydrochalone was performed through a two-enzyme cascade catalytic method, which solved the problem of complex extraction steps and low yields of 3-hydroxy trilobin, and achieved efficient and low-cost preparation, suitable for Massive production of 3-hydroxy trilobin.
Patent Information
- Application Number
- CN202411019740.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-29
- Publication Date
- 2024-11-15
AI Technical Summary
In the prior art, the extraction steps of 3-hydroxy trilobin are complex, have low yields and high costs, making it difficult to achieve industrial production, which limits its application in the pharmaceutical field.
Using the bienzyme cascade catalytic method, tyrosinase and rhamnosidase were used to carry out a two-step reaction of naringin dihydrochalone to prepare 3-hydroxy trilobin, which was catalyzed by enzymes and was highly efficient. Low-cost and efficient preparation.
It achieves a high yield of 3-hydroxy trilobin (up to 87%), simplifies the preparation process, reduces costs, is suitable for mass production, and promotes its practical application.
Smart Images

Figure CN118957005A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of organic synthesis, and in particular to a method for synthesizing 3-hydroxytrilobatin by double-enzyme cascade catalysis. Background Art
[0002] 3-Hydroxytrilobatin has a wide range of biological activities such as hypoglycemic, anti-oxidant, liver protection, and toxicity reduction, and has potential clinical application value. It can improve insulin resistance, increase glucose uptake, lower blood sugar, regulate the key enzyme G-6-Pase in gluconeogenesis, stabilize blood sugar, and has a positive effect on the prevention and treatment of diabetes. 3-Hydroxytrilobatin can also capture methylglyoxal (MG). MG is a glucose metabolite that is associated with peripheral neuropathy and pain in diabetic patients, and can also lead to poor healing of diabetic wounds. 3-Hydroxytrilobatin has an estrogen-like effect, which regulates estrogen levels and effects in the body by affecting the secretion of estrogen.
[0003]
[0004] In addition, 3-hydroxy trilobatin is also a good polyphenol antioxidant because it has 3,4-o-diphenolic hydroxyl groups on the aromatic ring. In 2010, Matthieu Gaucher et al. compared the antioxidant capacity of phloridzin, trilobatin and 3-hydroxy trilobatin by using the DPPH free radical model. The results showed that 3-hydroxy trilobatin was the compound with the highest antioxidant capacity among the three compounds. In 2018, Xiao Zhengcao found that 2', 4', 6'-trihydroxyacetophenone and 3, 4-o-diphenolic hydroxyl groups in dihydrochalcone are key pharmacophores, and the latter is more active than the former. Glycosylation of dihydrochalcone A ring will reduce the activity of 2', 4', 6'-trihydroxyacetophenone pharmacophore, but will enhance the activity of 3, 4-o-diphenolic hydroxyl pharmacophore (Xiao Zhengcao. Identification and in vitro activity and functional analysis of dihydrochalcone compounds in apple plants [D]. Shaanxi: Northwest Agriculture and Forestry University, 2018.). Therefore, 3-hydroxytrilobatin has broad application prospects in the field of medical treatment.
[0005] 3-Hydroxytrilobatin is a rare dihydrochalcone compound, mostly derived from the leaves of apple plants. However, the extraction steps are complicated and the yield is extremely low. The yield of 3-Hydroxytrilobatin in the leaves and young fruits of apple plants is shown in the following table (Xiao Zhengcao. Identification and in vitro activity and function analysis of dihydrochalcone compounds in apple plants [D]. Shaanxi: Northwest Agriculture and Forestry University, 2018.):
[0006] Species name Yield % M.sieboldii 2.20 M. 'RedSplendor' 0.63 Adams M. 'Adams' 1.90 M. 'Snowdrift' 1.92 Diamondleaf M. 'Sparkler' 1.16 M.'Donghongguo' 2.52 M. 'Adams' 0.56 M.sieboldii 0.62 M.'Donghongguo' 0.16 M. 'RedSplendor' 0.04
[0007] At present, the main preparation method of 3-hydroxy trilobatin is to extract and purify it from a few plant materials such as Hubei Begonia tea and Polyspicate sweet tea. In 2018, Xiao Zhengcao et al. freeze-dried the young fruits of Malus hongli and Malus weepingensis, and then ground them into powder. Extract with 80% ethanol. Filter, centrifuge, and dry the supernatant. Then add distilled water, ultrasonically homogenize into a turbid liquid, and extract three times with petroleum ether. Then the aqueous phase is extracted three times with ethyl acetate and dried. Then 3-hydroxy trilobatin is obtained through separation, purification and other steps. This method has long steps, complicated operation, low yield, unsafe and environmentally unfriendly.
[0008] In 2022, Li Jiajia et al. (Li Jiajia. Optimization of the separation system of dihydrochalcone in apple and study on its antibacterial activity against Streptococcus mutans [D]. Northwest A&F University, 2022.) extracted 3-hydroxytrefoil from the leaves of the hybrid of Malus frutescens and Malus adamsii, and optimized the extraction method, but there are still problems such as low yield, complex steps, long time, high cost, and difficulty in industrial production.
[0009] In summary, due to the low distribution and low content of 3-hydroxy trilobatin in nature, the low extraction efficiency in plants and the high price, its application research and development are greatly limited. Therefore, a method for preparing 3-hydroxy trilobatin at low cost and high efficiency is urgently needed to facilitate industrial production. Summary of the invention
[0010] In order to solve the above problems, the present invention provides a method for synthesizing 3-hydroxytrefoil by double enzyme cascade catalysis, taking naringin dihydrochalcone, which is an abundant source, as a substrate, and preparing 3-hydroxytrefoil by tyrosinase and rhamnosidase cascade catalyzing naringin dihydrochalcone reaction, and utilizing the site selectivity and high efficiency of enzyme catalysis to achieve low-cost and high-efficiency preparation of 3-hydroxytrefoil.
[0011] Specifically, the following technical solutions are provided:
[0012] The present invention provides a method for synthesizing 3-hydroxytrilobatin by double enzyme cascade catalysis, comprising the following steps:
[0013] (1) reacting naringin dihydrochalcone with tyrosinase and L-ascorbic acid in the presence of a solvent, and performing a temperature-raising inactivation treatment on the system after the reaction to obtain a mixed solution containing an intermediate;
[0014] (2) The mixed solution containing the intermediate is mixed with rhamnosidase to react to obtain 3-hydroxytrilobatin.
[0015] The present invention uses naringin dihydrochalcone, which is rich in sources, as a substrate, first uses tyrosinase and L-ascorbic acid to perform an oxidation-reduction reaction on the substrate, introduces a hydroxyl group to the naringin dihydrochalcone to form an intermediate, and then uses rhamnosidase to remove the rhamnosyl group of the intermediate to prepare 3-hydroxy trilobatin. The above-mentioned introduction of hydroxyl groups and removal of rhamnosyl groups are not replaceable. During the research and development process, the inventor tried to use rhamnosidase to first remove the rhamnosyl group from the substrate naringin dihydrochalcone, and then use tyrosinase to introduce hydroxyl groups. The results show that the target product 3-hydroxy trilobatin cannot be obtained; in addition, the inventor tried to directly use tyrosinase and L-ascorbic acid to perform an oxidation-reduction reaction on the substrate trilobatin to prepare 3-hydroxy trilobatin, but the reaction product of the above reaction does not contain the target product 3-hydroxy trilobatin, indicating that the hydroxylation modification reaction catalyzed by tyrosinase is selective for the substrate. It can be seen that in the synthesis method of 3-hydroxytrilobatin provided by the present invention, the type of substrate and the order of enzyme addition will affect the formation of the target product. When and only when the substrate is naringin dihydrochalcone, and tyrosinase and L-ascorbic acid are first used to carry out an oxidation-reduction reaction on the substrate, and then rhamnosyl is removed by rhamnosidase, the target product 3-hydroxytrilobatin can be obtained, and the yield of the target product is high.
[0016] The structure of naringin dihydrochalcone is as follows:
[0017]
[0018] Furthermore, in step (1), the ratio of the molar amount of the naringin dihydrochalcone to the mass of the tyrosinase is (5-100) mmol: (1-20) mg, for example, 20 mmol: 4 mg.
[0019] Furthermore, in step (1), the molar ratio of the naringin dihydrochalcone to the L-ascorbic acid is 1:(4-16), for example 1:8.
[0020] Furthermore, in step (1), the solvent comprises an organic solvent and a buffer solution; preferably, the organic solvent is selected from one or more of dimethyl sulfoxide, formamide, and N,N-dimethylformamide. Such organic solvents can dissolve the substrate naringin dihydrochalcone and have no inhibitory effect on enzyme activity; the buffer solution is a phosphate buffer solution with a pH of 6.0-8.0. Too high or too low a pH will affect enzyme activity, reduce conversion rate, and cause side reactions. In order to ensure reaction efficiency and increase the yield of the target product, the pH is preferably controlled between 6 and 8.
[0021] Furthermore, in step (1), naringin dihydrochalcone and L-ascorbic acid are first dissolved in the organic solvent, and then the buffer solution is added to fix the volume to obtain solution I; tyrosinase is dissolved in the buffer solution to form solution II; and solution I and solution II are mixed and reacted to obtain the mixed solution containing the intermediate; preferably, the mass percentage of the organic solvent in the solution I is 10%-30%.
[0022] Furthermore, in step (1), the reaction temperature is 20-40°C.
[0023] Furthermore, in step (1), the temperature of the temperature-raising inactivation treatment is 80-100°C.
[0024] Furthermore, the ratio of the molar amount of the naringin dihydrochalcone to the mass of the rhamnosidase is preferably (5-100) mmol: (6-130) mg, for example 20 mmol: 26 mg, 20 mmol: 50 mg, etc.; the present invention does not impose an upper limit on the amount of rhamnosidase used, and the greater the amount of rhamnosidase used, the faster the reaction.
[0025] Furthermore, in step (2), the pH of the mixed solution containing the intermediate is 5.0-7.0.
[0026] Furthermore, in step (2), the reaction temperature is 40-50°C.
[0027] Furthermore, step (2) also includes the following operations: adding an organic solvent to the system after the reaction to terminate the reaction, collecting the filtrate by centrifugal filtration, and obtaining 3-hydroxytrilobatin powder by rotary evaporation, dialysis, and freeze-drying; the organic solvent is selected from one or more of methanol, acetonitrile, and ethanol.
[0028] Furthermore, the volume of the organic solvent added is 2-3 times the volume of the system after the reaction.
[0029] Compared with the prior art, the present invention has the following beneficial effects:
[0030] The invention provides a method for synthesizing 3-hydroxy trilobatin by double enzyme cascade catalysis. The 3-hydroxy trilobatin is obtained by subjecting naringin dihydrochalcone to a two-step enzyme catalysis reaction. The raw material source is abundant, easily available and low in cost. The synthesis method is simple and easy to operate, and the reaction conditions are mild and the time is short. The yield of 3-hydroxy trilobatin synthesized by the synthesis method can be as high as 87%. The method is suitable for the mass production of 3-hydroxy trilobatin and is conducive to promoting the practical application of 3-hydroxy trilobatin. BRIEF DESCRIPTION OF THE DRAWINGS
[0031] Figure 1 HPLC chart of the pure 3-hydroxytrilobatin prepared in Example 1;
[0032] Figure 2 This is the LC-MS chart of the pure 3-hydroxytrilobatin prepared in Example 1;
[0033] Figure 3 The pure 3-hydroxy trilobatin prepared in Example 1 1 H-NMR spectrum;
[0034] Figure 4 The pure 3-hydroxy trilobatin prepared in Example 1 13 C-NMR spectrum;
[0035] Figure 5 HPLC comparison of the filtrate prepared in Example 1 (tyrosinase plus rhamnosidase in the figure) and Comparative Example 1 (rhamnosidase plus tyrosinase in the figure) and the reference substance 3-hydroxytrilobatin;
[0036] Figure 6 It is a HPLC comparison chart of the product prepared in Comparative Example 2, the raw material trilobatin and the reference substance 3-hydroxytrilobatin. DETAILED DESCRIPTION
[0037] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used herein in the specification of the present invention are only for the purpose of describing specific embodiments and are not intended to limit the present invention. The term "and / or" used herein includes any and all combinations of one or more related listed items.
[0038] The present invention is further described below in conjunction with the accompanying drawings and specific embodiments so that those skilled in the art can better understand the present invention and implement it, but the embodiments are not intended to limit the present invention.
[0039] Unless otherwise specified, the experimental methods used in the following examples are all conventional methods, and the materials, reagents, etc. used are all available from commercial sources unless otherwise specified.
[0040] Example 1
[0041] This example relates to the preparation of 3-hydroxy trilobatin, and the specific operation is as follows:
[0042] 2.0 mL of 20 mM naringin dihydrochalcone solution (containing 160 mM L-ascorbic acid and 25% DMSO) and 2.0 mL of tyrosinase solution (4 mg / mL, 0.1 M phosphate buffer, pH 7.0) were added to a Jusai test tube, mixed, reacted at 25°C for 10 h, then inactivated at 100°C, cooled to 50°C, added 26 mg of rhamnosidase, and reacted for 1 h. The reaction was then terminated with 4 mL of methanol, centrifuged at 10000 rpm for 10 min, and then microfiltered with a 0.22 μm filter membrane. The filtrate was subjected to rotary evaporation, dialysis, and freeze-dried to obtain 3-hydroxytrilobatin powder with a yield of 87%.
[0043] Take 2.0 mg of 3-hydroxytrilobatin powder, add 0.5 mL of methanol to dissolve, filter and put into a sample injection bottle, and perform HPLC and LC-MS detection and analysis.
[0044] The HPLC detection method is as follows:
[0045] Chromatographic column: CS-Chromatographie Service GmbH C18 column (250 mm×4.6 mm, 5 μm); mobile phase: acetonitrile-0.2% acetic acid aqueous solution (75:25, V / V); flow rate: 1.0 mL / min; detection time: 20 min; detection wavelength: 282 nm; injection volume: 10 μL.
[0046] The HPLC diagram of the product is as follows Figure 1 As shown, the retention time is 5.6 min.
[0047] The LC-MS analysis results of the product are as follows Figure 2 As shown, the molecular weight of the product tested in negative ion mode (450.9 in the figure is [M-1] - The molecular weight of the target product 3-hydroxytrilobatin was consistent with that of the target product 3-hydroxytrilobatin.
[0048] Weigh 10.0 mg of 3-hydroxytrilobatin powder, add 0.5 mL of deuterated DMSO to dissolve, put into an NMR tube, and perform 1 H-NMR and 13 C-NMR detection, the test results are as follows Figure 3 , 4 As shown, it is further verified that the product prepared in this example is 3-hydroxytrilobatin.
[0049] Comparative Example 1
[0050] 2.0 mL of 20 mM naringin dihydrochalcone solution (containing 160 mM L-ascorbic acid and 25% DMSO) was added to a stoppered test tube, and 2.0 mL of rhamnosidase solution (26 mg / mL, 0.1 M phosphate buffer, pH 7) was added to start the reaction. After reacting at 50°C for 1 hour, the reaction was inactivated at 100°C, cooled to 25°C, 4 mg of tyrosinase was added, and the reaction was continued for 4 hours. The reaction was then terminated with 4 mL of methanol, centrifuged at 10000 rpm for 10 minutes, and then filtered with a 0.22 μm filter membrane, and the filtrate was analyzed by high performance liquid chromatography.
[0051] Figure 5 The HPLC comparison chart of the filtrate prepared in Example 1, the filtrate prepared in Comparative Example 1 and the reference substance 3-hydroxy trilobatin (HPLC test conditions are the same). It can be seen from the figure that the product prepared in this comparative example is complex and does not contain the target product 3-hydroxy trilobatin. It can be seen that the target product cannot be prepared by changing the order of adding tyrosinase and rhamnosidase.
[0052] Comparative Example 2
[0053] 2.0 mL of 20 mM trilobatin solution (containing 160 mM L-ascorbic acid and 25% DMSO) and 2.0 mL of tyrosinase solution (4 mg / mL, 0.1 M phosphate buffer, pH 7.0) were added to a stoppered test tube, mixed, and reacted at 25° C. for 4 h. The reaction was then terminated with 4 mL of methanol, centrifuged at 10,000 rpm for 10 min, and then microfiltered with a 0.22 μm filter membrane for liquid chromatography analysis.
[0054] Figure 6 The HPLC comparison chart of the product prepared in this comparative example and the reference substances trilobatin and 3-hydroxy trilobatin (HPLC test conditions are consistent). It can be seen from the figure that the product prepared in this comparative example is complex and does not contain the target product 3-hydroxy trilobatin. It can be seen that the target product 3-hydroxy trilobatin cannot be prepared by replacing the substrate and directly oxidizing and reducing trilobatin.
[0055] The above-mentioned embodiments are only preferred embodiments for fully illustrating the present invention, and the protection scope of the present invention is not limited thereto. Equivalent substitutions or changes made by technicians in the technical field on the basis of the present invention are all within the protection scope of the present invention. The protection scope of the present invention shall be subject to the claims.
Claims
1. A method for synthesizing 3-hydroxytrilobatin by dual enzyme cascade catalysis, It is characterized in that The following steps are involved: (1) reacting naringin dihydrochalcone with tyrosinase and L-ascorbic acid in the presence of a solvent, and performing a temperature-raising inactivation treatment on the system after the reaction to obtain a mixed solution containing an intermediate; (2) The mixed solution containing the intermediate is mixed with rhamnosidase to react to obtain 3-hydroxytrilobatin.
2. The method according to claim 1, It is characterized in that In step (1), the ratio of the molar amount of the naringin dihydrochalcone to the mass of the tyrosinase is (5-100) mmol: (1-20) mg; The molar ratio of the naringin dihydrochalcone to the L-ascorbic acid is 1:(4-16).
3. The method according to claim 1, It is characterized in that In step (1), the solvent comprises an organic solvent and a buffer solution; The organic solvent is selected from one or more of dimethyl sulfoxide, formamide, and N,N-dimethylformamide; The buffer solution is a phosphate buffer solution with a pH value of 6.0-8.
0.
4. The method according to claim 3, It is characterized in that In step (1), naringin dihydrochalcone and L-ascorbic acid are first dissolved in the organic solvent, and then the buffer solution is added to the fixed volume to obtain solution I; tyrosinase is dissolved in the buffer solution to form solution II; Then, the solution I and the solution II are mixed and reacted to obtain the mixed solution containing the intermediate; The mass percentage of the organic solvent in the solution I is 10%-30%.
5. The method according to claim 1, It is characterized in that In step (1), the reaction temperature is 20-40°C.
6. The method according to claim 1, It is characterized in that In step (1), the temperature of the temperature-raising inactivation treatment is 80-100°C.
7. The method according to claim 1, It is characterized in that The ratio of the molar amount of the naringin dihydrochalcone to the mass of the rhamnosidase is (5-100) mmol: (6-130) mg.
8. The method according to claim 1, It is characterized in that In step (2), the pH of the mixed solution containing the intermediate is 5.0-7.0; The temperature of the mixed reaction is 40-50°C.
9. The method according to claim 1, It is characterized in that Step (2) further comprises the following operations: adding an organic solvent to the system after the reaction to terminate the reaction, collecting the filtrate by centrifugal filtration, and obtaining 3-hydroxytrilobatin powder by rotary evaporation, dialysis, and freeze-drying; the organic solvent is selected from one or more of methanol, acetonitrile, and ethanol.
10. The method according to claim 9, It is characterized in that The volume of the organic solvent added is 2-3 times the volume of the system after the reaction.
